We are committed at APIS Assay Technologies, to realise the clinical potential of systems biology and medicine in the diagnosis and personalisation of treatment. We seek to develop biomarkers that deliver significant improvements in the prediction and prevention of disease. There are 3 main workstreams of our business: 1. Biomarker Industrial Research Programme. This structured R&D programme undertakes industrial research on biomarker-based diagnostic assays, targeting oncology, inflammatory, cardiovascular, infectious disease and inherited disease areas. 2. The ‘Fast-Tracking’ of Biomarkers and Diagnostic Platforms for market sale. 3. The Contract Development activity operates as a distinct commercial service line, with focus on the tailored development of novel molecular diagnostic tests on new medical diagnostic platforms.